MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions.
Hiroki SatoAdam J SchoenfeldEvan SiauYue Christine LuHuichun TaiKen SuzawaDaisuke KubotaAllan J W LuiBesnik QeriqiMarissa MattarMichael D OffinMasakiyo SakaguchiShinichi ToyookaAlexander E DrilonNeal X RosenMark G KrisDavid SolitElisa De StanchinaMonika A DavareGregory J RielyMarc LadanyiRomel SomwarPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
We demonstrate that downstream activation of the MAPK pathway can mediate of innate acquired resistance to ROS1 TKIs and that patients harboring ROS1 fusion and concurrent downstream MAPK pathway alterations have worse survival. Our findings suggest a treatment strategy to target both aberrations.
Keyphrases
- signaling pathway
- cell death
- dna damage
- oxidative stress
- reactive oxygen species
- end stage renal disease
- pi k akt
- immune response
- newly diagnosed
- peritoneal dialysis
- free survival
- gene expression
- squamous cell carcinoma
- patient reported outcomes
- copy number
- combination therapy
- young adults
- replacement therapy
- rectal cancer